AustralianSuper Pty Ltd Buys 671,258 Shares of Pfizer Inc. $PFE

AustralianSuper Pty Ltd increased its position in Pfizer Inc. (NYSE:PFE) by 16.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 4,650,032 shares of the biopharmaceutical company’s stock after acquiring an additional 671,258 shares during the quarter. AustralianSuper Pty Ltd’s holdings in Pfizer were worth $115,786,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Horizon Financial Services LLC lifted its stake in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares in the last quarter. YANKCOM Partnership purchased a new position in shares of Pfizer during the 4th quarter valued at $28,000. Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer during the 3rd quarter valued at $29,000. Darwin Wealth Management LLC bought a new position in shares of Pfizer in the second quarter worth $32,000. Finally, Torren Management LLC purchased a new stake in shares of Pfizer in the fourth quarter worth $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on PFE shares. Guggenheim lifted their price objective on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Royal Bank Of Canada reaffirmed an “underperform” rating and issued a $25.00 price target on shares of Pfizer in a report on Monday, April 20th. Barclays began coverage on Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target for the company. Morgan Stanley boosted their price objective on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Finally, HSBC upped their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $28.84.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won European Commission approval to expand HYMPAVZI (marstacimab) for hemophilia A or B patients with inhibitors, a new label expansion that could support future revenue growth. Pfizer wins Hympavzi label expansion Europe
• Positive Sentiment: Pfizer also highlighted ongoing pipeline progress, including a new Japan RSV vaccine phase 3 trial and a prazosin site-transfer study, signaling continued development activity and supply-chain execution. Pfizer’s New Japan RSV Vaccine Trial Pfizer’s Prazosin Site-Transfer Trial
• Positive Sentiment: Some commentary argues Pfizer has effectively “locked in” several years of growth by clearing a major patent hurdle and redirecting cash toward other profit centers, which supports the bull case. Pfizer Just Locked In Its Next 5 Years of Growth

Pfizer Trading Down 0.8%

NYSE PFE opened at $25.74 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The stock’s 50-day simple moving average is $27.01 and its two-hundred day simple moving average is $26.19. Pfizer Inc. has a twelve month low of $22.09 and a twelve month high of $28.75. The company has a market capitalization of $146.70 billion, a price-to-earnings ratio of 19.65 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.